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stucly, Three hundrecl twenty.flve patlents[277AF/48AF1; 84% male: avemge 
age • 67 yeam; dumtlon of AF/AFI, R wesks-7 months; NYHA: I ,  28%, II 
ù 64%, III - 8%] wem randomlzed to 1 of 4 treatmant gmups: 
Dofetltldo 125 mag, 250 mag, 500 mag, er placebo BID, The numher of 
pstlentl who aehlevnd N.~R allor 3 dlys of oral doslng wem ss follows: 
plsoebo 1/82 (1%), dofetlUde 125 mag 5/74 (6%), dofatlllda 280 m~ 8/79 
(t0,1%), dofetlllda 600 mag 23/71 (32%), Advoma arrests wem batanced 
aeron tmmlment gmups, No tomsdss ner daaths o~urmd, 
Con¢luslon: We oonclude that oratly ~dmlntsfere(:l dofatlllde at 500 me0 
0lD Il effo¢tlvo and safe In convarllng ehmnl0 atrtal flbrlllstlonffluttar fo normel 
slnul dlylhm, 
10:45 
~ IntrlvengUl Vlnlul In Rlolnl Proplfenono Olgoxln 
Onnt Atdld Flbtlllotlon. A PlllOebo-eontmltN, 
Rlmdomllmd 81udy 
L, Btlm~nl, On tJetmtf of R4FIT.3 Inv~fl~tom; $, Flllt~oo Net~ Hospltal, 
~n( / :  Intmv~nouo pmp~fenone (Pmp) h{ls been ehown to eJff~tlv~ly 
metom slnus ~hythm In moent onsal +tilgst flbflll+ltton (AF), whlle tha alfto+lW ot 
Iv dl~o~in (Olg) hu  b~n quolltlonod, Howovor, ~ dlmot ~oml~dllon mono 
thxa dn~lll i~nd plaoebo (Pl~le) le still I~~klng, 
Malfto~: Oßa hundr~ tw~nty lhmo pte wlth AF lasttn9 <7~ hm wem 
mndomlzed 1o silber Iv Pmp (g mg/Kg, 41 p~) or Iv O19 (0,5 mg, 40 ptel) or 
Plao (4~ pte), After 1 hour, non,eonvened Pmp o~ D~ 9 pts wem ewltohed to 
lho oll~r d~~l, whlll non,oonv~rt«] PIke pt~ wem mndoml~ed to nlthm iv 
Pmp er Dt9 and monltomd for a lurthet heer, 
R~uffa: A~r  the first tmatn'~nt, 20/41 (49%) Pmp pts wem onrdlove~~d, 
venlus 12/40 Ot9 pta (32%) and 6/42 Pilz0 ple (14%), The table sparte the 
mlldlve e111¢l~y (RE) of the dnlgs oslculMad by IOglStlo mgmsslon anatysls, 
Am~ng the 47 pt~ mstant to the filet t~tmant who wem 8wlt¢hed to the 
altem•tlve dmg, Olg was effectlva in t/20 pts (5%) nnd Pmp in 12/~7 (48%) 
pla (p < O,OS). tn the 35 w0n-convel1~l Pl8e p~ elloeafed to ~n ~¢tlve dmg, 
slnus rhythm was obtalmKI in 10/19 pts (53%) by Prop and in 1118 pts (5%) 
by Dl9 (p < O.OS). ConsltJeting all the 118 pts who 11~"elved a dn~g as a first 
~tl~l tmalment, ~onvenllon rotes wem 50% (30R0 pl~) wlth Pmp and R5% 
(14/S8 pt~) wlth Olg (p < O,0t, C,I, 95%1,2-3,4), No etgnifi~ant stde efle(:ts 
wem obsonmd In any pts. 
RE C,I, 95% p 
Prop vs Plac 3.41 1,53-?,63 .0.01 
I~g vz PI~ 2E7 0,9e-,~.40 NS 
Prop va 0t 9 1 50 097-2,59 NS 
Conc/usk~: In m,.-'ent onset AF Iv pmpafenone festeres s~nus mylhm 
mom effectlvely than etther plac'flbo r tv dtgoxln, 
11:00 
~ Effi©ll¢y and Safety o1 Intmvonous Flecslnlde 
Compamd to ami  Qulnldlne tor  Convemlon o1 Acute 
Atdld Flbri l latlon (AF) to Slnus Rhythm In Patlents 
P~tlreated Wlth Intravenous Metoprolo l  - The 
FLEQUIN Trlal 
M.O, Hallr~n, A. Pulkklnen, J, Mustonen, M, Puhakka, M. Huftunen, 
S, Paskklnen, L, l~rssanen, M, NIsslnen, J, Melln, T, OIll, Dept, of Medlclne. 
Kz~WO Un~~erstly I'fOS~tal, Kuopto; 4 Central Hospltats, Easfem, Finland 
Ob~ves:  We sfodled the efficacy and safety oi i.v. flecalntdo compamd 
wlth erst qulnldlne for the convemion of saufe AF after Lv. metoprolol was 
glven to Iower ventrlcular ufe, 
~¢k~ound: Eftectlve and safe treatment oi saufe AF is needod in the 
emelgency team. A detay in conversion to slnus rhythm (SR) prolongs the 
hosplfel t~tment and Incmases costs. 
Methoats.' A randomiseck double blind comparison between flecainide (2 
mg/kg wlthtn 30 min.) and qulnldlne (200 mg up to 3 tlmes 2 hr apart) was 
perfon~ed In 163 patlents wlth acufe (<48 hours) AF after metoprolol was 
given openly. 
Resutts: SR was restored within three hours in 45 (54"/0) of the 83 patlents 
In the flecainldo group and in 24 (30%) of the 80 park nts in the qulntdine 
group (p = 0.0018). DC cardlovemion was needed in 23% and lq% of 
patlents (14,S.), and the medien detays to SR ware 0.8 hours and 4.1 hours 
in the fleealnk~e end quintdine gmups, respectlvely (p < 0,001), The medien 
hosplfet sfe:, ~-I p~tients not needing DC ~'~rdloverslon a d pmlonged hospital 
stay (>48 ht) ~^'a~ 6,4 hr in the flecainide group and 9,4 hr in the quinidine 
group, (p = 0,012). Asymptomatic pauses of 3-9.8 seconds wem found in 
ambulstoty ECG recording of 8 patients in the flecalnlde group and of 7 
patients in the quinidine group. Two patients in the flecainido group had a 
shorl lasting circulatory collapse. 
Conclualons: Fle~alnlde actod mom rapldly In mstodn9 8R than qulnldlne. 
Both druga wem safe for the tmalment of outpatient~ in the emergeney 
room, I,v, metopmtol was a safe pmtmatment for petionts tmated wlth etther 
flecalnlde or qulntdlne, 
11:15 
~ A©ut~ Atrlol Flbrl l lat lon' Hlgh,l~N IV Amlodorone 
Fu l l i to tu  Convemlon to  Nofmol  81nus Rhylhm. 
When is it Ne~ss l ry?  
G, Cottor, E, Coltet.Melzkor, E. Kalulki, A, 0tat, Y, M01~kovltz, I Ulk~ky, 
M, Komn, R. Zt|ldensfeln, A, Gollk, Amf.P~n~#ft Me(J~al O#nt~, 
tarne/ 
The rate of epontsneoul ¢onwrelon of ~ Iztfial fibd!lat!on (A« AF) to 
normal sinus dlythm (NBR) le high and not affo¢tod by Iow ¢lole lmto¢lemee 
(Am,) trimtnl~nt, We lvaloltt¢l high.deN Am, in 1ha tfelftllent et A~D AF. 
Metho~: Etghty pallanta (ptl,) wlth parox~mat AF, ~ for A~~ AF 
(,~48 h) wem random~ed to m¢elve for 24 t~um: (1) Group A, (n = 40); 
Pl~l~bo (R) Group 6, (n ~ 40): ~H1tlnuou8 IV Am, 120 mg/h~f (tl~M 3 9), 
Group A pta, not oonvolttn9 to NSR wtfhin 24 bi' wem ommled ~ to Am 
Ihempy, All p~, meeWed OIgoxln, 
Resut~; Basellna pulea was 1~7 ± 19 beafi/min, and ± al beatMmm, in 
gmups A and B, in group A, 2? pilz, (67%) (xmveltod 1o NSR w. 3B (90%) in 
group B (p .  0,029), ~nty. fhte of 27 (93%) pls, ¢~~,e~nQ SlXmtaneoulW 
(in group A) have ¢onverted within t 2 hmlm, Eleven pts, (85%) in t~ B not 
+co~~!11111g on plaeetlo have c~nvetted after being ~ O~ef to 
Am, t~tment, Flnally, 0 pt~, (in both gmup~) dtd not colwe~t on 
Am,, 3 ~ve~KI  a~tot ele¢td~l ~rdlovefetoß, ~ all 6 wem in ch~ AF 
after 1 month, In p~, still In AF ~fter 8 houm et tmatme~, the putse fete 
deemased to 114 :E 20 txlafe/m~n, ingroup A v*. 83 ± 15 beets/min, tn graue 
B (p = 0.0014). No advefse event~ mquldng tmalment O¢¢UnIKI in (Imu~ B 
pts. 
t 
Cot¢lusk~n: IV high-dose Am. tmatment (120 mg/ht) is safe and lacilitates 
convemlon O1 Ac AF to NSR. Spontaneous conve~sion commonty occurs 
wlthln 12 hours, themtom, high-dose Am. may be resen~ed for pts. mquiring 
rate control, tang form Am. tmatment er not convefling within 12 heus. Pts 
resistant 1o high-dose Am. am at high risk of developing chronic AF. 
11:30 
~ ~ 7  Class III Drugs for  Suppress ion  of  Recurrent 
Symptomatic Atrktl F ibdl lat ion 
G.E. Kochiadakts, N.E. Igoumentdis, M.E. Marketou, M.C. Solomou, 
E.M. Kanoupakis, P.E. Vardas. C.aro'/ofogy Dept., Hersklion University 
Hospital. Cmte. Gmece 
Background: In this comparative trist, we examined the efficacy and safety of 
amtodamne and sotatol in maimaining nom~t sinus rhythm in patients (pts) 
with retractonj atdal fibfitlatton. 
Methods: Seventy consecutive pts (39 men, mean age 63.1 ± 9 years) 
,ver: randomized into two clinicatly similar groups: 35 received amiodamne 
and 33 sutalot. Pts with ejection fractton <40% er clinlcatly significant heal~ 
disease wem excluded, The amiodamne dosage began with 800 to 1600 
mg/day for 7 to 14 doys oralty and was then fepered over 7 to 12 days, gen- 
erally to 200 mgtday. The sotatol dosage was 160-360 mgtday, as *.olo=t~d. 
Fotlow up clinlcai evatuations wem conducted at 2 month intewals tor the first 
6 months and at 3 month Intetvals thereafter. The propodion of pts mmaining 
in slnus rhy~hl~~ was calculafed for the two groups using the Kaplan-Mefer 
method. 
Results: Ten o1 the 35 p~ on amiodamne developed atrial fibrillation 
during the 12-month obsewation period, compared to 21 of the sotalol group 
(p = 0.008). Progmssion to atriat fibrillation was faster in the sotaloi pts 
(p = 0,012): after 6 months, 77.4% of amiodamne pts remained in normal 
sinus rhythm compared to 54.3% of the sotalol pts, whife at 12 months the 
respective percentages wem 71% and 40%. Sex, age, left atdat size and 
atrial fibrillation type had no significant effect. 
